We determined the molecular basis of cystathionine (3-syn thase (CBS) deficiency in a partially pyridoxine-responsive homocystinuria patient. Direct sequencing of the entire CBS cDNA revealed the presence of a homozygous G 133flA transition. This m utation causes an am ino acid change from aspartic acid to asparagine (D444N) in the regulatory do m ain of the protein and abolishes a T aqI restriction site at D N A level. Despite the homozygous m utation, CBS activi ties in extracts of cultured fibroblasts of this patient were not in the homozygous but in the heterozygous range. F u r thermore, we observed no stim ulation of CBS activity by S-adenosylmethionine, contrary to a threefold stim ulation in control fibroblast extract. The m utation was introduced in an E. coli expression system and CBS activities were measured after addition of different S-adenosylmethionine concentrations (0-200 jiM). Again, we observed a defective stimulation of CBS activity by S-adenosylm ethionine in the m utated construct, whereas the norm al construct showed a threefold stim ulation in activity. These data suggest th at this D444N m utation interferes in S-adenosylmethionine regulation of CBS. Furtherm ore, it indicates the im portance of S-adenosylmethionine regulation of the transsulfuration pathw ay in homocysteine homeostasis in hum ans. (J. Clin. Invest 1996. 98:285-289.) Key words: homocysteine • cys tathionine (3-synthase deficiency * genetic m utation • in vitro expression • methionine
Introduction
Homocystinuria due to cystathionine (3-synthase (CBS,1 L-serine hydro-lyase [adding homocysteine], EC 4.2.1.22) defi-ciency is an inborn error of methionine metabolism. CBS-deficiency is inherited as an autosomal recessive trait and is clini cally characterized by premature arteriosclerosis and thrombosis, ectopia lentis, skeletal abnormalities, and m ental retardation 0 . 2 ).
In a large international survey of 629 homocystinuria pa tients, Mudd et al. (3) showed that about 50% of these patients were considered pyridoxine responsive, i.e., a large decrease in homocysteine concentrations was obtained upon administra tion of pharmacological doses of pyridoxine (vitamin B 6 ), the precursor of the co-factor for CBS.
CBS catalyzes the condensation of homocysteine and serine to cystathionine, an irreversible step in the transsulfuration pathway. This catalytic active enzyme consists of four identical subunits. T he C B S gene has been mapped to the subtelomeric segment of chromosome 21: 2 iq22.3 (4) and encodes a subunit of 63 kD.
Several imitations have been reported in the human C B S cD N A (5-7), of which most were screened for pathogenicity in a bacterial or yeast expression system (8 ,9) . T he mutations de scribed so far, are located in the catalytic domain of the pro tein (amino acids 1 to 418; J.P. Kraus, unpublished results), with some clusters of mutations in exon 3 and 8 (10) . No m uta tions have been reported in the regulatory domain of this pro tein.
S-Adenosylmethionine (A doM et), an intermediate in the conversion of methionine to homocysteine, is the methyl do nor in various transmethylation reactions including nucleic ac ids, neurotransmitters, phospholipids, and hormones. It is an im portant regulator of homocysteine/methionine metabolism (11, 12) , by stimulating CBS activity about threefold (13) and decreasing the formation of 5-methylenetetrahydrofolate by inhibition of m ethylenetetrahydrofolate reductase (M THFR). The result of elevated A doM et levels is a decreased remethylation of homocysteine to m ethionine and an enhanced clear ance of homocysteine via the transsulfuration pathway.
In this report, we describe a homocystinuria patient with severely elevated homocysteine concentrations, but with CBS activities in cultured fibroblasts in the heterozygous range. D N A analysis revealed a novel m utation in the regulatory do main of the CBS protein. We were able to correlate this m uta tion to a defective regulation of the CBS protein by A doM et in both fibroblasts and an E. coli expression system, which pro vides evidence for the im portant regulatory function of A doM et in homocysteine metabolism.
Methods
Patient. The patient is a woman, now 20 y of age, who had been ad mitted to the hospital at the age of nine years because of psychomotoric retardation and marfanoid features such as excessive height, Defective Cystathionine ß-Synthase Regulation in Homocystinuria dolichostenomelia, and arachnodactyly. The diagnosis homozygous homocystinuria has been made then, and since she is treated with a combination of pyridoxine (vitamin B6, 500-750 mg daily), folic acid (5 mg daily), and betaine (6 grams daily). At present time, i.e., 11 y af ter diagnosing and start of therapy, she is in a very good physical con dition and her intellectual development has reached an average level. Her length is 182 cm and weight 75 kg. She has not any physical com plaint. Ectopia lentis, osteoporosis, and vascular complications did not occur until now.
Biochemical analysis, Determination of homocystine, homocysteine-cysteine mixed disulphide and methionine in serum of the pa tient was performed as described earlier by us (14) . The amount of nonprolein-bound homocysteine was calculated as twice the concen tration of homocystine plus the concentration of the homocysteinecysteine mixed disulphide. Total plasma homocysteine concentra tions, consisting of the total amount of protein and nonprotein-bound homocysteine, of a sister were determined according to Te Poele-Pothoff et al. (15) .
CBS activities in extracts of cultured skin fibroblasts were deter mined in the absence and presence of 1 mM pyridoxal 5'-phosphate (PLP) or different concentrations of AdoMet, essentially according to Engbersen et al. (16) . Activities are expressed in nmol cystathionine formed per mg protein per hour at 37°C.
Methylenetetrahydrofolate reductase (MTHFR) activity was measured in isolated lymphocytes (16) in the absence and presence of 75 or 400
AdoMet, and in cultured fibroblasts (17) . The specific MTHFR activity is expressed in nmol formaldehyde formed per mg protein per hour. Protein concentrations were determined as de scribed by Lowry et al. (18) . Folate and vitamin B12 concentrations were determined in heparinized plasma by routine hospital assays.
Mutation analysis. Genomic DNA was isolated from peripheral blood leukocytes according to a protocol by Miller et al. (19) . Total RNA was extracted from cultured fibroblasts (20) and stored as an ethanol precipitate at -80°C. A 5 ;xg sample of RNA was reverse transcribed to cDNA in 1 h at 42°C with 200 units of Superscript II re verse transcriptase (Life Technologies, Breda, The Netherlands), us ing oligo(dT) and random hexamer primers. 1 /xl of this first-strand cDNA was subjected to PCR amplification. The oligonucleotides used were described elsewhere (7) . These amplifications were carried out in a total volume of 100 jud, containing 100 ng forward and reverse primer, 200 pJVl each dNTP, 10 mM Tris-HCl pH 8.3,50 mM KC1,1.5 mM MgCl2, 0.01% gelatin and 1 unit 7'aq polymerase (Life Technolo gies, Breda, The Netherlands). Amplification parameters were as fol lows: 35 cycles of 92°C/60 s (denaturation), 52-58°C/60 s (annealing) and 72°C/90 s (extension). The cycles were preceded by an initial de naturation step of 5 min at 95°C and were followed by a final exten sion of 7 min at 72°C.
By PCR, we generated three overlapping fragments which cov ered the entire coding region. Direct sequencing of these products was performed using the Taq Dye Deoxy™ Terminator Cycle Se quencing Kit according to the manufacturer's recommendations (Ap plied Biosystems, Forster City, CA). The dye-labeled sequencing products were purified by phenol/chloroform extraction and ethanol precipitation at room temperature. The pellets were washed in 70% ethanol, solubilized in loading buffer (96% deionized formamide, 20 mM EDTA, pH 8.0, dextran blue) and electrophoresed in a 6% poly acrylamide/8 M urea sequencing gel on a ABI 373A DNA sequencer. All PCR fragments were sequenced on both strands.
Genomic D N A amplification. To confirm the mutation at the ge nomic DNA level, a fragment consisting of exon 11, intron 11 and exon 12 was amplified in the same PCR buffer as described above, us ing forward primer 5' -G ACC A A GTTCCTG AGCG A C AGGTG-3' (cDNA 1146-1169) and reverse primer 5'-CCCGCCTCATCCAC-CACGG-3' (cDNA 1358-1340). Amplification conditions were as follows: 5 min initial denaturation at 95°C, 35 cycles of 92°C/60 s, 59°C/60 s and 72°C/45 s, followed by a final extension of 7 min at 72°C. TaqI restriction enzyme analysis was performed according to the recommendations of the manufacturer (Life Technologies, Breda, The Netherlands). Restriction fragments were resolved in a 15% polyacrylamide gel containing 5% glycerol. Ethidium bromide staining was used to visualize the restriction fragments.
Cloning and expression o f the mutation. The cDNA fragment con taining the mutation was amplified by PCR and subcloned into an expression cartridge derived from pHCS3, using BstXI and Kpnl, as described extensively (8, 21) . E . coli JM109 cells were transformed and recombinants were selected by PCR and restriction enzyme anal ysis. The integrity of the mutated clone was established by sequencing analysis. Expression of the CBS cDNA was induced by IPTG addi tion (21) and the CBS enzyme assay (16) was performed without ad dition of BSA to the incubation mixture. Cystathionine (Sigma, Am sterdam, The Netherlands) was added to a final concentration of 2 mM.
Results
Biochemical analysis. Hyperhomocysteinemia and hypermethioninemia were observed in our patient when compared to controls (Table I) . Daily administration of 500 mg pyridoxine for six weeks resulted in only a minor reduction of homocys teine levels of ^3 0 % . Additional administration of folic acid (5 mg daily, for 6 wk) and later on also of betaine (6 grams daily, for 6 wk) resulted in a marked decrease in homocys teine, however homocysteine was still elevated compared to controls (Table I) . Therapy left methionine concentrations vir tually unchanged. In her sister, total plasma homocysteine con centration (protein plus nonprotein-bound) was elevated in fasting state (26 fimol/liter; reference values: 6-15 fjimol/liter) and after a methionine-loading test (72 fjimol/Iiter; reference values: 18-51 ¡¿mol/liter).
Folate concentration prior to treatment was 10 nmol/liter (control values: 5 .5^0 nmol/liter) and vitamin B 12 concentra tion was 180 pmol/liter (control values: 150-380 pmol/liter).
Specific M TH FR activity was normal in isolated lympho cytes of our patient (12.6, reference values: 9.1-23.9 nmol CH20/m g protein.h; n = 18) as well as in cultured fibroblasts (6.2, reference values: 4.9-10.0 nmol CH20/m g protein.h; n -6 ). In isolated lymphocytes, we found the same inhibition by AdoM et as observed in control lymphocytes (data not shown). She was found to be heterozygous for the previously described 677 C->T transition in the M THFR gene (22).
Extracts of cultured fibroblasts were assayed for CBS activ ity in the presence and absence of 1 mM PLP, as shown in Ta- ble II. Both measurements show CBS activities in the het erozygous range which is in contrast to the severely elevated homocysteine levels observed in this patient, D N A analysis of the CBS cDNA was performed to explore the genetic basis un derlying this contradiction. DNA analysis. We synthesized three sets of oligonucle otides which enabled us to amplify overlapping fragments cov ering the entire CBS cDNA. The PCR fragments generated were all of the expected size, suggesting the existence of point mutations rather than small deletions, insertions or splice error mutations in the cDNA of this patient.
Direct sequencing of the entire coding region revealed a novel homozygous G 133oA missense mutation. No other se quence aberrations could be detected in the CBS cDNA. This mutation is expected to cause an amino acid change from as partic acid (GAC) to asparagine (AAC) at position 444 of the mature protein (D444N), i.e., a negatively charged amino acid is replaced with a neutral one. The mutation abolished a TaqI restriction site which was used to confirm the mutation at the genomic D N A level. Screening of both parents and an unaf fected sister revealed their heterozygous state for this transi tion (Fig. 1 ). We were unable to detect this mutation among 14 other Dutch homozygotes for CBS deficiency, indicating that this transition is rare among Dutch homocystinurics. The D444N substitution was not observed in 80 control chromo somes.
In vitro expression and AdoMet regulation. The pathogenic nature of the G1330A transition was investigated both in cul tured fibroblasts and in an E. coli expression system. CBS as says in extracts of cultured fibroblasts were performed after addition of different AdoM et concentrations to the incubation mixture. As shown in Fig. 2 , AdoMet stimulates CBS activity about threefold in control fibroblasts, contrary to virtually no stimulation observed in fibroblast extracts of the patient.
We cloned the cDNA fragment, containing the G1330A transition, into an expression cartridge to restore the CBS cDNA in plasmid pHCS3. The presence of the mutation and the absence of artifacts introduced by PCR were confirmed by sequence analysis of the cloned fragment and its cloning sites (data not shown). Cell lysates were analyzed for CBS activity in the presence of different concentrations of AdoM et (0-200 [xM; Fig, 3 ). This figure clearly demonstrates that CBS activity in the mutant is indistinguishable from the control when m ea sured in the absence of AdoMet. AdoMet, however, is unable to stimulate the CBS protein with the D444N substitution to the same extent as the CBS protein translated from the control construct, which is stimulated threefold. 
Discussion
Severe hyperhomocysteinemia, as observed in our patient, may be caused by a homozygous deficiency in CBS or M THFR, two regulating enzymes in homocysteine m etabo lism. In this study, we detected a novel G^A (D444N) mis sense mutation in the regulatory dom ain of the CBS protein, which is associated with a defective regulation of the CBS pro tein by AdoMet. Until now, about 18 mutations have been described in the CBS gene in patients with homocystinuria due to CBS defi ciency (5) (6) (7) . Some mutations seemed to be rather unique to one family, while others, especially the I278T (21) and G307S (23), occur more frequently. All mutations described so far, are located in the NH2-terminal domain and are thought to in terfere in the catalytic activity of the enzyme.
AdoM et concentration (jumol/L)
In our patient, we detected an apparent mild D444N m uta tion in the regulatory domain of the CBS protein, implying a mild CBS deficiency. However, the clinical manifestations and the severe hyperhomocysteinemic status of the patient and the moderate hyperhomocysteinemia of the heterozygous sister, indicate that this mutation may interfere in a very important regulation of CBS activity.
In extracts of cultured fibroblasts, we observed an excep tionally high residual CBS activity for a homocystinuria pa tient compared to 14 other diagnosed CBS deficient patients (Table II) . Homocystinuria patients described so far, exhibited dramatically decreased CBS activities in cultured fibroblasts. However, Uhlendorf, Bittles and their co-workers (24, 25) , de scribed each a homocystinuria patient with CBS activities in the heterozygous or low-normal range. They ascribed these findings to either a very mild homozygous CBS deficiency, or to a heterozygous deficiency with hepatic CBS activities un usually low for heterozygotes, which could lead to homocysti nuria. According to our data, those patients may be homozy gotes for CBS deficiency defective in CBS regulation.
Expression of the D444N m utation was performed in an E. coli expression system (8 , 21) . CBS enzyme expressed in E. coli is indistinguishable from hum an CBS enzyme present in cultured fibroblasts. It is able to bind PLP, heme and AdoM et and exhibits catalytic activity (2 1 , 26). Activities ob tained when expressing the m utant construct were equal to those observed in the control construct in the absence of AdoMet. Thus, the m utation has no pathogenic nature in the absence of AdoM et in our in nature of the mutation: it interferes in the regulation of the CBS protein by AdoMet.
The E. coli expression with our mutant CBS construct showed a normal basal activity, contrary to fibroblasts, in which we observed a reduced basal activity. However, the ef fect of a mutation on protein activity in cultured fibroblasts cannot be compared directly with its effect in E. coli. It is known that mutant polypeptides are degraded more rapidly in cultured fibroblasts than in E . coli, which has also been dem onstrated for mutant CBS subunits (21) . The discrepancy ob served may depend on differences in protein catabolism be tween both systems, heme status (important in CBS function) and the concentration of stabilizing (co)-factors.
Although our experiments in the E. coli expression system show that this D444N mutation is causing a regulatory defect, we were unable to exclude a possible influence of the mutation on CBS activity in liver, the main site of homocysteine catabo lism. The mutation may also have an effect on protein synthe sis and/or turnover of CBS in liver affecting hepatic CBS activ ity and plasma homocysteine concentration in this patient. For ethical reasons we were unable to obtain a liver specimen to address this issue, AdoMet is an allosteric regulator of the homocysteine flux through either the transsulfuration or remethylation pathway. Low levels of AdoM et favor the conservation of the homocysteine-skeleton of methionine, whereas high levels of AdoMet stimulate the irreversible conversion of homocysteine to cys tathionine in the transsulfur ation pathway (12). The disruption of this regulation of homocysteine metabolism may explain the severe hyperhomocysteinemia observed in our patient. Due to the homozygous G l330A transition in the CBS gene, AdoMet is unable to stimulate CBS, so a surplus of homocysteine will not be degraded via the transsulfuration pathway. Furthermore, the elevated AdoM et levels will inhibit M TIiFR, resulting in an additional accumulation of homocysteine.
M THFR deficiency was excluded as a possible contributor to hyperhomocysteinemia. Specific M THFR activity in iso lated lymphocytes as well as in cultured fibroblasts of our pa tient was well within the reference range, excluding a major defect in MTHFR. Furthermore, regulation of MTHFR by AdoM et was found to be normal. The patient is heterozygous for the previously described 677C->T transition in the M THFR gene. The prevalence of this heterozygous state in the Dutch population is ~ 40% (27, 28) . In homozygous state, this mutation is associated with elevated homocysteine con centrations (22, 27, 28), especially in circumstances of low (normal) folate (29). Plasma homocysteine concentrations in heterozygotes however, do not differ significantly from those observed in wild-type individuals (22, [27] [28] [29] ). An interaction between lowered folate and plasma homocysteine has only been described in individuals with the homozygous mutant genotype and not in heterozygous individuals (29).
Comparison of the human CBS to the rat enzyme and sev eral homologous cysteine synthases from plants and bacteria (5) , indicates an extensive homology in the NHz-terminal part of these proteins. This N H 2-terminal domain, encoded by exon 1 to 12, is believed to bind both substrates (homocysteine and serine), heme, and its cofactor PLP. The COOH-terminal do main of the CBS protein is only conserved in rat CBS (30) and partly in yeast CBS (9) , in which also the aspartic acid-444 res idue is conserved, but is absent in O-acetylserine (thiol)-lyase (cysK) from E. coli (31) . However, this latter enzyme, which shows 52% sequence similarity to human CBS, catalyzes the formation of cysteine from O-acetyl-L-serine and inorganic sulfide and not the homocysteine conversion into cystathionine in this organism. Although the enzymatic function is different, both enzymes, CBS, and cysK, condense serine and a sulfur containing compound to either cystathionine or cysteine.
Pathogenicity of the G 1330A mutation was ascertained by four different methods. First, we found no other mutations in the coding region of the CBS gene, which could be responsible for the severely elevated homocysteine and methionine levels. Second, the mutation was absent in 80 control alleles, indicat ing that it is not a benign polymorphism. Third, the wild-type aspartic acid-444 residue is conserved in the evolution, which is evidence for functional relevance of this amino acid in the bio logical function of the protein. Fourth, we observed a defective regulation of CBS by AdoMet in extracts of cultured fibro blasts of this patient and in a prokaryotic expression system in which we introduced this mutation.
To our knowledge, this is the first report of a mutation in the regulatory domain of the CBS protein. W e have provided substantial evidence that the D444N substitution is a patho genic mutation and interferes in the normal regulation of the CBS protein by AdoMet, although a possible effect on CBS synthesis and turnover in liver could not be excluded. From a diagnostic point of view, we urge others to include an AdoM et-dependent enzyme assay in the diagnosis of ho mocystinuria, because similar patients could be missed in the regular screening methods, which could lead to a false conclu sion regarding the origin of homocystinuria in such patients.
